Sidmak Laboratories (india) Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Sidmak Laboratories (india) Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $5.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Sidmak Laboratories (india) Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $5.5M Trade | TransData Nexus

Sidmak Laboratories (india) Private Limited

Indian Pharmaceutical Exporter · CNS & Psychiatric Specialist · $5.5M Total Trade · DGFT Verified

Sidmak Laboratories (india) Private Limited is an Indian pharmaceutical exporter with a total trade value of $5.5M across 3 products in 2 therapeutic categories. Based on 110 verified export shipments from Indian Customs (DGFT) records, Sidmak Laboratories (india) Private Limited is the #1 Indian exporter in 1 product including Fluoxetine. Top exports include Fluoxetine ($5.0M), Nitrofurantoin ($365.0K), Minocycline ($140.6K).

Sidmak Laboratories (india) Private Limited — Export Portfolio & Destination Treemap

Sidmak Laboratories (india) Private Limited pharmaceutical export portfolio — 3 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Sidmak Laboratories (india) Private Limited? — Company Overview & Market Position

Sidmak Laboratories (India) Private Limited, established in 1983, is a prominent Indian pharmaceutical exporter specializing in the development and manufacturing of finished pharmaceutical formulations. The company operates under the Corporate Identification Number (CIN) U24230GJ1983PTC006157 and is registered with the Registrar of Companies, Ahmedabad. Its registered office is located at S. No. 4662, 4663, and 4779 & 4785, N. H. No. 48, Abrama, P. B. No. 121, Valsad, Gujarat, India, 396001.

Sidmak Laboratories is a private, non-government company with an authorized share capital of ₹50 million and a paid-up capital of ₹18.085 million. The company is unlisted and has been actively engaged in the pharmaceutical sector for over four decades. As of June 2025, Sidmak Laboratories employed over 500 qualified personnel, reflecting its significant presence in the industry.

What Does Sidmak Laboratories (india) Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Fluoxetine$5.0M 2

Product Portfolio — Top 3 by Export Value

Sidmak Laboratories (india) Private Limited exports 3 pharmaceutical products across 2 therapeutic categories. Market leader (#1 exporter) in 1 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Fluoxetine	CNS & Psychiatric	$5.0M	99	2.1%	1
2	Nitrofurantoin	Advanced Antibiotics	$365.0K	8	1.1%	15
3	Minocycline	Advanced Antibiotics	$140.6K	3	0.6%	11

Sidmak Laboratories (india) Private Limited exports 3 pharmaceutical products across 2 therapeutic categories with a total export value of $5.5M. The company is the #1 Indian exporter in 1 product: Fluoxetine. The top category is CNS & Psychiatric (90.7% of portfolio), followed by Advanced Antibiotics (9.3%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Sidmak Laboratories (india) Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Sidmak Laboratories operates two state-of-the-art manufacturing facilities in India:

Valsad Plant: Located in Gujarat, this facility is WHO-GMP certified and specializes in the production of various pharmaceutical formulations, including tablets, capsules, and transdermal drug delivery systems.

Dehradun Plant: Situated in Uttarakhand, this plant is approved by the US FDA and focuses on the manufacturing of controlled-release tablets, bi-layered tablets, coated and uncoated tablets, enteric-coated tablets, film-coated tablets, hard gelatin capsules, transdermal, and topical patches.

Both facilities are equipped with advanced technology platforms and adhere to stringent quality control measures, ensuring the production of high-quality pharmaceutical products.

3Key Leadership

Sidmak Laboratories is led by a team of experienced directors:

Dhananjay Thakorbhai Desai: Director since February 6, 2008.

Uday Ratilal Shah: Whole-Time Director since April 7, 2010.

Vinayak Tulsidas Bhalani: Director since September 26, 1996.

These leaders have been instrumental in steering the company towards growth and innovation in the pharmaceutical industry.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Sidmak Laboratories (india) Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Sidmak Laboratories has established a strong presence in several regulated markets:

United States: The Dehradun facility is approved by the US FDA, enabling the company to export pharmaceutical products to the U.S. market.

European Union and United Kingdom: While specific regulatory approvals are not detailed, the company's adherence to international quality standards suggests potential market access.

Australia and Japan: There is no publicly available information regarding regulatory approvals or market access in these regions.

Sidmak Laboratories' compliance with global regulatory standards positions it favorably for expansion into these markets.

2Emerging Markets

Sidmak Laboratories has made strategic inroads into emerging markets:

Sidmak Laboratories (india) Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Sidmak Laboratories' Dehradun facility holds approval from the US FDA, allowing the company to manufacture and export pharmaceutical products to the United States. Specific details regarding FDA facility registrations, approved ANDAs, DMF filings, and inspection history are not publicly available.

2WHO & EU GMP

Sidmak Laboratories' Valsad facility is WHO-GMP certified, ensuring compliance with international quality standards. Specific information regarding EU GMP certificates and EDQM status is not publicly available.

3CDSCO & Indian Regulatory

Sidmak Laboratories holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and state drug controllers, facilitating its operations within India. The company's adherence to Indian regulatory standards underscores its commitment to quality and compliance.

Recent Regulatory Actions

Sidmak Laboratories (india) Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Sidmak Laboratories operates in a competitive pharmaceutical export market, contending with both domestic and international companies. While specific competitors are not identified, the company's focus on CNS & Psychiatric and Advanced Antibiotics categories positions it in direct competition with firms specializing in these therapeutic areas.

2Key Differentiators

Sidmak Laboratories' key strengths include:

Regulatory Approvals: FDA approval for the Dehradun facility and WHO-GMP certification for the Valsad plant.

Product Portfolio: A concentrated portfolio with a strong presence in the CNS & Psychiatric category.

Manufacturing Capabilities: State-of-the-art facilities capable of producing a wide range of pharmaceutical formulations.

Strategic Position

Buyer Due Diligence Brief — Evaluating Sidmak Laboratories (india) Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Sidmak Laboratories has a commendable track record in the pharmaceutical industry, with over 40 years of experience. The company's export volume and consistency, as evidenced by 110 shipments valued at $5.5 million USD, reflect its reliability. The absence of regulatory actions further underscores its dependability as a supplier.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and compliance:

FDA Approval: Confirm the Dehradun facility's FDA approval status.

WHO-GMP Certification: Verify the Valsad facility's WHO-GMP certification.

EU GMP Certification: Assess the company's compliance with EU GMP standards.

Frequently Asked Questions — Sidmak Laboratories (india) Private Limited

How many pharmaceutical products does Sidmak Laboratories (india) Private Limited export from India?

Sidmak Laboratories (india) Private Limited exports 3 pharmaceutical products across 2 therapeutic categories. The top exports are Fluoxetine ($5.0M), Nitrofurantoin ($365.0K), Minocycline ($140.6K). Total export value is $5.5M.

What is Sidmak Laboratories (india) Private Limited's total pharmaceutical export value?

Sidmak Laboratories (india) Private Limited's total pharmaceutical export value is $5.5M, based on 110 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Sidmak Laboratories (india) Private Limited the #1 Indian exporter?

Sidmak Laboratories (india) Private Limited is the #1 Indian exporter in 1 products: Fluoxetine (2.1% market share).

What therapeutic categories does Sidmak Laboratories (india) Private Limited cover?

Sidmak Laboratories (india) Private Limited exports across 2 therapeutic categories. The largest are CNS & Psychiatric (90.7%, 1 products), Advanced Antibiotics (9.3%, 2 products).

Get Full Sidmak Laboratories (india) Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.